Effect of interleukin-10 on serum tumor necrosis factor-α in gastric cancer rats

Abstract

Objective To investigate the effect of interleukin-10 on serum tumor necrosis factor-α in gastric cancer rats. Methods The mice were randomly divided into two groups: control group, model group and treatment group, n=20. At the 12th week after operation, the mice in the treatment group were treated with intraperitoneal injection of interleukin (IL)-10 for 10 000 U/time and 2 times per week. In the control group, the model group was injected with the same amount of saline. All mice were sacrificed at the 20th week after the operation. Serum IL-10, tumor necrosis factor-α (TNF-α), interferon (IFN)-γ and IL-4 levels were measured by enzyme linked immunosorbent assay (ELISA). The levels of spleen CD4+ CD25+ , CD3+ , CD4+ and CD8+ were detected by flow cytometry. Lactate dehydrogenase (LDH) cytotoxicity was used to detect the cytotoxicity of natural killer (NK) cells and CD8+ T cells in vitro. Results Serum IL-10, TNF-α, IFN-γ, and IL-4 levels in the treatment group were (28.96±6.35), (92.15±12.01), (2.58±0.72), and (10.19±2.56) ng/L, respectively. The levels of serum IL-10, TNF-α, IFN-γ and IL-4 in each group were significantly different (F=2.595, 2.273, 3.403, 5.159, P=0.032, 0.026, 0.012). Serum IL-10, IFN-γ and IL-4 levels in the treatment group were significantly higher than those in the model group (t=2.351, 2.159, 2.235, P=0.015, 0.028, 0.020). Serum TNF-α levels were significantly lower than those in the model group (t=2.159, P=0.028). In the treatment group, CD4+ CD25+ , CD3+ , CD4+ , and CD8+ were 5.86±1.02, 58.55±20.52, 26.17±7.35, and 15.38±2.55, respectively. There were significant differences in spleen CD4+ CD25+ , CD3+ , CD4+ , and CD8+ among mice in each group (F=3.398, 2.385, 5.056, 2.302, P=0.012, 0.018, 0.000, 0.026). The spleen CD4+ CD25+ and CD3+ in the treatment group were significantly lower than those in the model group (t=2.302, 2.175, P=0.025, 0.039), and the CD4+ and CD8+ T levels were significantly higher than those in the model group (t=2.159, 2.285, P=0.033, 0.026). The LDH leakage rates of NK cells and CD8+ T cells in the treatment group were (172.31±22.69) U/L and (159.78±18.37) U/L, respectively. The LDH leakage rate of NK cells and CD8+ T cells in each group was significantly different (F=2.102, 2.595, P=0.038, 0.011). The LDH leakage rate of NK cells and CD8+ T cells in the treatment group was significantly lower than that in the model group (F=2.356, P=0.025). Conclusion The establishment of mouse gastric cancer model, IL-10 treatment to improve the level of IL-10 in vivo, can significantly improve serum levels of IFN-γ and IL-4, reduce TNF-α levels, improve T cell levels and NK cells, CD8+ T Cell killing ability, play an anti-tumor effect. Key words: Gastric cancer; Interleukin-10; Serum tumor necrosis factor-α